Efficacy of istradefylline for gait disorders with freezing of gait in Parkinson’s disease: A single-arm, open-label, prospective, multicenter study

Could istradefylline be a treatment option for postural abnormalities in mid-stage Parkinson's disease?

(2018) Keisuke Suzuki et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

The effectiveness of istradefylline for the treatment of gait deficits and sleepiness in patients with Parkinson’s disease

(2018) Keita Matsuura et al.   NEUROSCIENCE LETTERS

Caffeine as symptomatic treatment for Parkinson disease (Café-PD)

(2017) Ronald B. Postuma et al.   NEUROLOGY

Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial

(2016) Emily J Henderson et al.   LANCET NEUROLOGY

A Long-Term Study of Istradefylline Safety and Efficacy in Patients With Parkinson Disease

(2015) Tomoyoshi Kondo et al.   CLINICAL NEUROPHARMACOLOGY

Freezing of gait: a practical approach to management

(2015) Jorik Nonnekes et al.   LANCET NEUROLOGY

Adenosine A2Areceptor antagonist istradefylline reduces daily OFF time in Parkinson's disease

(2013) Yoshikuni Mizuno et al.   MOVEMENT DISORDERS

Neurophysiology of gait: From the spinal cord to the frontal lobe

(2013) Kaoru Takakusaki   MOVEMENT DISORDERS

In vitro pharmacological profile of the A2A receptor antagonist istradefylline

(2013) Mayumi Saki et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex

(2013) Takako Kadowaki Horita et al.   PSYCHOPHARMACOLOGY

Adenosine A2A Antagonists in Parkinson’s Disease: What’s Next?

(2012) Patrick Hickey et al.   Current Neurology and Neuroscience Reports

Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials

(2012) Lorraine V. Kalia et al.   MOVEMENT DISORDERS

Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease

(2010) David Devos et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

24-Hour Recording of Parkinsonian Gait Using a Portable Gait Rhythmogram

(2010) Hiroshi Mitoma et al.   INTERNAL MEDICINE

Quantification of Indirect Pathway Inhibition by the Adenosine A2a Antagonist SYN115 in Parkinson Disease

(2010) K. J. Black et al.   JOURNAL OF NEUROSCIENCE

The clinical spectrum of freezing of gait in Parkinson's disease

(2010) Yasuyuki Okuma et al.   MOVEMENT DISORDERS

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study

(2010) Yoshikuni Mizuno et al.   MOVEMENT DISORDERS

Predictors of future falls in Parkinson disease

(2010) G. K. Kerr et al.   NEUROLOGY

Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)

(2008) Peter A. LeWitt et al.   ANNALS OF NEUROLOGY